TLDR Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
This case report highlights the successful use of baricitinib, a JAK 1/2 inhibitor, in a 16-year-old female with chronic immune thrombocytopenia (cITP) and alopecia areata, where conventional treatments failed. Baricitinib, used off-label, significantly improved platelet counts and alopecia, with sustained normal platelet levels post-treatment. The findings suggest baricitinib as a potential treatment for pediatric cITP with autoimmune conditions, warranting further clinical trials to validate its efficacy.
148 citations,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
3 citations,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
17 citations,
January 2019 in “Journal of cutaneous medicine and surgery” JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
1 citations,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.